Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants
Phase 1 Study to Determine the Safety, Infectivity, and Tolerability of Two Doses of Live Attenuated Recombinant Cold Passaged (cp) 45 Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3 102A, Delivered as Nose Drops to Infants 6 to 12 Months of Age, and to HPIV3 Seronegative Infants and Children 6 to 36 Months of Age
Sponsor: Johns Hopkins Bloomberg School of Public Health
This PHASE1 trial investigates Paramyxoviridae Infections and Virus Diseases and is currently completed. Johns Hopkins Bloomberg School of Public Health leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Jun 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Johns Hopkins Bloomberg School of Public Health
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .